Search

Deadlines & Announcements

New announcements will be published as soon as new elements for the Congress Sponsor Program for EHA2024 are released.

Faculty information

We are honored that you have agreed to be part of the faculty for the Highlights of Past EHA (HOPE) Latin America (LA) 2023, to be held on October 26, 2023 in São Paulo, Brazil.

We are honored that you have agreed to be a part of the faculty for the EHA-KCS Hematology Tutorial – Recent Advances in Lymphoid and Myeloid Malignancies, scheduled to be held on September 13-14, 2024 in Almaty, Kazakhstan.

Faculty Information

We are honored that you have agreed to be a part of the faculty for the EHA-TSH Hematology Tutorial on T Cell Lymphomas, scheduled to be held on June 29-30, 2024 in Ankara, Türkiye.

Social Media Learning

EHA presents our own microlearning in 4 formats, covering diagnosis, pathology, clinical schemas, and clinical cases within topics in the European Hematology Curriculum.

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Jun 12 2015 Posted in Press releases

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Faculty Information

We are honored that you have agreed to be part of the faculty for the EHA-ISHBT Hematology Tutorial, to be held on March 1-3, 2024 in Hyderabad, India.